Predictors of initiating rapid-acting insulin analog using vial/syringe, prefilled pen, and reusable pen devices in patients with type 2 diabetes

Journal of Diabetes Science and Technology

Volumn 4, Issue 3, 2010, Pages 547-557

  Lee, Lauren J ^a   Anderson, Julie ^b   Foster, Shonda A ^a   Corrigan, Sheila M ^c   Smith, David M ^b   Curkendall, Suellen ^b  

^a ELI LILLY AND COMPANY   (United States)

^b THOMSON REUTERS   (United States)

^c Lilly Corporate Center   (United States)

Author keywords

Insulin; Pen device; Type 2 diabetes mellitus; Vial

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN;

ARTICLE; DISPOSABLE EQUIPMENT; DRUG SELF ADMINISTRATION; FEMALE; HUMAN; INSTRUMENTATION; MALE; METHODOLOGY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; SYRINGE; UTILIZATION REVIEW;

DIABETES MELLITUS, TYPE 2; DISPOSABLE EQUIPMENT; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SELF ADMINISTRATION; SYRINGES;

EID: 78349289688     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681000400307     Document Type: Conference Paper

References (24)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2008. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007. pdf.
2. Oglesby AK, Secnik K, Barron J, Al-Zakwani I, Lage MJ. The association between diabetes related medical costs and glycemic control: a retrospective analysis. Cost Eff Resour Alloc. 2006;4:1.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86.
6. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
7. Riddle MC. Timely initiation of basal insulin. Am J Med. 2004;116 Suppl 3A:3S-9S. (Pubitemid 38167751)
8. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27(1):17-20. (Pubitemid 38196703)
9. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218-24. (Pubitemid 38579798)
10. Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ. 2007;33(6):1014-29.
11. Ary DV, Toobert D, Wilson W, Glasgow RE. Patient perspective on factors contributing to nonadherence to diabetes regimen. Diabetes Care. 1986;9(2):168-72. (Pubitemid 16080472)
12. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543-5. (Pubitemid 41384310)
13. Molife C, Lee LJ, Shi L, Sawhney M, Lenox SM. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther. 2009;11(8):529-38.
14. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32(1 Suppl):9S-18S. (Pubitemid 43206838)
15. Polonsky WH. Emotional and quality-of-life aspects of diabetes management. Curr Diab Rep. 2002;2(2):153-9.
16. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10):1712-25. (Pubitemid 44841979)
17. Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL. Health outcomes and economic impact of therapy conversation to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27(7):948-62. (Pubitemid 46986681)
18. Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007;29(6 Pt 1):1294-305. (Pubitemid 351172225)
19. Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care. 2008;31(3):430-2.
20. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-9.
21. Borah BJ, Darkow T, Bouchard J, Aagren M, Forma F, Alemayehu B. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clin Ther. 2009;31(3):623-31.
22. McAdam-Marx C, Yu J, Bouchard J, Aagren M, Brixner DI. Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin. Curr Med Res Opin. 2009;26(1):191-201.
23. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12. (Pubitemid 46161090)
24. Sadur CN, Moline N, Costa M, Michalik D, Mendlowitz D, Roller S, Watson R, Swain BE, Selby JV, Javorski WC. Diabetes management in a health maintenance organization. Efficacy of care management using cluster visits. Diabetes Care. 1999;22(12):2011-7. (Pubitemid 30433981)